<p>Chimerix, Inc. (NASDAQ:CMRX - 获取免费报告) 的股价在周二的午盘交易中创下了新的 52 周高点。该股最高交易价格为 8.54 美元，最后交易价格为 8.53 美元，成交量为 192094 股。该股此前收盘价为 8.52 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>CMRX 已成为几份分析师报告的主题。Wedbush 在 3 月 5 日的研究报告中重申了 “中性” 评级，并将 Chimerix 的目标价上调至 8.55 美元（之前为 7.00 美元）。HC Wainwright 在 3 月 5 日的研究报告中重申了 “中性” 评级，并将 Chimerix 的目标价下调至 8.55 美元（之前为 11.00 美元）。StockNews.com 在周二开始对 Chimerix 进行覆盖。他们对该股设定了 “持有” 评级。最后，Jefferies Financial Group 在 3 月 5 日的报告中重申了 “持有” 评级，并将 Chimerix 的目标价下调至 8.50 美元（之前为 10.00 美元）。</p>
<p><strong>查看我们关于 Chimerix 的最新研究报告</strong></p>
<h2>Chimerix 股票表现</h2>
<p>该股市值为 7.9968 亿美元，市盈率为-9.07，贝塔值为-0.17。该公司的 50 日移动平均线为 6.41 美元，200 日移动平均线为 3.45 美元。</p>
<p>Chimerix (NASDAQ:CMRX - 获取免费报告) 最近在 3 月 21 日发布了季度财报。这家生物制药公司报告本季度每股收益为-0.25 美元，超出分析师一致预期的-0.26 美元，超出幅度为 0.01 美元。该公司本季度的收入为 6 万美元，而分析师预期为 31 万美元。股票分析师预测 Chimerix, Inc.将在本年度发布-0.99 的每股收益。</p>
<h2>Chimerix 的内部交易</h2>
<p>在其他消息中，首席执行官 Michael T. Andriole 在 2 月 13 日的交易中出售了 7370 股公司的股票。这些股票的平均售价为 4.52 美元，总价值为 33312.40 美元。交易完成后，首席执行官现在直接持有 609603 股公司股票，价值约为 2755405.56 美元。这代表了他们持股比例的 1.19% 的减少。该出售在向证券交易委员会提交的文件中披露，您可以通过此链接访问。过去三个月，内部人士共出售了 20760 股公司股票，价值 91175 美元。目前，内部人士持有该股的比例为 13.10%。</p>
<h2>Chimerix 的机构交易</h2>
<p>一些机构投资者和对冲基金最近对该股的持仓进行了调整。Assenagon Asset Management S.A.在第四季度将其在 Chimerix 的持股增加了 154.8%。Assenagon Asset Management S.A.现在拥有 817739 股这家生物制药公司的股票，价值 2846000 美元，此前在上一季度又购买了 496823 股。Charles Schwab Investment Management Inc.在第四季度获得了 Chimerix 的新头寸，价值 183000 美元。Rosalind Advisors Inc.在第四季度购买了 Chimerix 的新头寸，价值约为 10614000 美元。Palumbo Wealth Management LLC 在第四季度购买了 Chimerix 的新股份，价值约 221000 美元。最后，Valeo Financial Advisors LLC 在第四季度将其在 Chimerix 的持股增加了 78.8%。Valeo Financial Advisors LLC 现在拥有 146186 股这家生物制药公司的股票，价值 509000 美元，此前在上一季度又购买了 64420 股。目前，机构投资者和对冲基金持有该股的比例为 45.42%。</p>
<h2>关于 Chimerix</h2>
<p>(获取免费报告)</p>
<p>Chimerix, Inc.是一家生物制药公司，开发药物以改善和延长面临致命疾病的患者的生命。其管线产品包括 ONC201，一个正在进行针对 H3 K27M 突变弥漫性胶质瘤患者的三期临床试验的项目，以及针对罕见神经内分泌肿瘤的二期临床试验；ONC206，一种 imipridone，Dopamine Receptor D2 (DRD2) 拮抗剂和 caseinolytic protease P (ClpP) 激动剂，正在进行针对成人和儿童原发性中枢神经系统肿瘤的一期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Chimerix</li>
<li>如何从价值投资中获利</li>
<li>关税防护股票：3 个具有巨大上涨潜力的大便宜货</li>
<li>在 52 周高点盈利交易股票</li>
<li>高通股价下跌但相对强弱指数显示其严重超卖</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>特斯拉的头号看涨者下调目标价但表示仍然值得买入</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Chimerix 吗？</h2>
<p>在你考虑 Chimerix 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Chimerix 并不在名单上。</p>
<p>虽然 Chimerix 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMRX

<p>Chimerix（纳斯达克代码：CMRX）创下 12 个月新高 - 原因如下</p>

<p>Chimerix, Inc. (NASDAQ:CMRX - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $8.54 and last traded at $8.53, with a volume of 192094 shares. The stock had previously closed at $8.52.</p>
<div class="lb-trans"><p>Chimerix, Inc. (NASDAQ:CMRX - 获取免费报告) 的股价在周二的午盘交易中创下了新的 52 周高点。该股最高交易价格为 8.54 美元，最后交易价格为 8.53 美元，成交量为 192094 股。该股此前收盘价为 8.52 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>CMRX has been the subject of several analyst reports. Wedbush reiterated a &#34;neutral&#34; rating and issued a $8.55 target price (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright reaffirmed a &#34;neutral&#34; rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com began coverage on Chimerix in a research note on Tuesday. They set a &#34;hold&#34; rating on the stock. Finally, Jefferies Financial Group restated a &#34;hold&#34; rating and set a $8.50 price target (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th.</p>
<div class="lb-trans"><p>CMRX 已成为几份分析师报告的主题。Wedbush 在 3 月 5 日的研究报告中重申了 “中性” 评级，并将 Chimerix 的目标价上调至 8.55 美元（之前为 7.00 美元）。HC Wainwright 在 3 月 5 日的研究报告中重申了 “中性” 评级，并将 Chimerix 的目标价下调至 8.55 美元（之前为 11.00 美元）。StockNews.com 在周二开始对 Chimerix 进行覆盖。他们对该股设定了 “持有” 评级。最后，Jefferies Financial Group 在 3 月 5 日的报告中重申了 “持有” 评级，并将 Chimerix 的目标价下调至 8.50 美元（之前为 10.00 美元）。</p>
</div><p><strong>Check Out Our Latest Research Report on Chimerix</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Chimerix 的最新研究报告</strong></p>
</div><h2>Chimerix Stock Performance</h2>
<div class="lb-trans"><h2>Chimerix 股票表现</h2>
</div><p>The stock has a market capitalization of $799.68 million, a PE ratio of -9.07 and a beta of -0.17. The business's 50-day moving average is $6.41 and its two-hundred day moving average is $3.45.</p>
<div class="lb-trans"><p>该股市值为 7.9968 亿美元，市盈率为-9.07，贝塔值为-0.17。该公司的 50 日移动平均线为 6.41 美元，200 日移动平均线为 3.45 美元。</p>
</div><p>Chimerix (NASDAQ:CMRX - Get Free Report) last issued its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.31 million. Equities analysts forecast that Chimerix, Inc. will post -0.99 EPS for the current year.</p>
<div class="lb-trans"><p>Chimerix (NASDAQ:CMRX - 获取免费报告) 最近在 3 月 21 日发布了季度财报。这家生物制药公司报告本季度每股收益为-0.25 美元，超出分析师一致预期的-0.26 美元，超出幅度为 0.01 美元。该公司本季度的收入为 6 万美元，而分析师预期为 31 万美元。股票分析师预测 Chimerix, Inc.将在本年度发布-0.99 的每股收益。</p>
</div><h2>Insider Transactions at Chimerix</h2>
<div class="lb-trans"><h2>Chimerix 的内部交易</h2>
</div><p>In other news, CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders have sold a total of 20,760 shares of company stock worth $91,175 in the last three months. 13.10% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Michael T. Andriole 在 2 月 13 日的交易中出售了 7370 股公司的股票。这些股票的平均售价为 4.52 美元，总价值为 33312.40 美元。交易完成后，首席执行官现在直接持有 609603 股公司股票，价值约为 2755405.56 美元。这代表了他们持股比例的 1.19% 的减少。该出售在向证券交易委员会提交的文件中披露，您可以通过此链接访问。过去三个月，内部人士共出售了 20760 股公司股票，价值 91175 美元。目前，内部人士持有该股的比例为 13.10%。</p>
</div><h2>Institutional Trading of Chimerix</h2>
<div class="lb-trans"><h2>Chimerix 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. boosted its holdings in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock worth $2,846,000 after buying an additional 496,823 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Chimerix during the 4th quarter worth $183,000. Rosalind Advisors Inc. bought a new position in shares of Chimerix in the fourth quarter valued at approximately $10,614,000. Palumbo Wealth Management LLC bought a new stake in Chimerix during the fourth quarter valued at about $221,000. Finally, Valeo Financial Advisors LLC grew its stake in shares of Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock worth $509,000 after acquiring an additional 64,420 shares during the last quarter. 45.42% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对该股的持仓进行了调整。Assenagon Asset Management S.A.在第四季度将其在 Chimerix 的持股增加了 154.8%。Assenagon Asset Management S.A.现在拥有 817739 股这家生物制药公司的股票，价值 2846000 美元，此前在上一季度又购买了 496823 股。Charles Schwab Investment Management Inc.在第四季度获得了 Chimerix 的新头寸，价值 183000 美元。Rosalind Advisors Inc.在第四季度购买了 Chimerix 的新头寸，价值约为 10614000 美元。Palumbo Wealth Management LLC 在第四季度购买了 Chimerix 的新股份，价值约 221000 美元。最后，Valeo Financial Advisors LLC 在第四季度将其在 Chimerix 的持股增加了 78.8%。Valeo Financial Advisors LLC 现在拥有 146186 股这家生物制药公司的股票，价值 509000 美元，此前在上一季度又购买了 64420 股。目前，机构投资者和对冲基金持有该股的比例为 45.42%。</p>
</div><h2>About Chimerix</h2>
<div class="lb-trans"><h2>关于 Chimerix</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.</p>
<div class="lb-trans"><p>Chimerix, Inc.是一家生物制药公司，开发药物以改善和延长面临致命疾病的患者的生命。其管线产品包括 ONC201，一个正在进行针对 H3 K27M 突变弥漫性胶质瘤患者的三期临床试验的项目，以及针对罕见神经内分泌肿瘤的二期临床试验；ONC206，一种 imipridone，Dopamine Receptor D2 (DRD2) 拮抗剂和 caseinolytic protease P (ClpP) 激动剂，正在进行针对成人和儿童原发性中枢神经系统肿瘤的一期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Chimerix</li>
<li>How to Profit From Value Investing</li>
<li>Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Qualcomm Breaks Down But RSI Signals It’s Severely Oversold</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Chimerix</li>
<li>如何从价值投资中获利</li>
<li>关税防护股票：3 个具有巨大上涨潜力的大便宜货</li>
<li>在 52 周高点盈利交易股票</li>
<li>高通股价下跌但相对强弱指数显示其严重超卖</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>特斯拉的头号看涨者下调目标价但表示仍然值得买入</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Chimerix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Chimerix 吗？</h2>
</div><p>Before you consider Chimerix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Chimerix 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Chimerix 并不在名单上。</p>
</div><p>While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Chimerix 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Chimerix（纳斯达克代码：CMRX）创下新的 52 周高点 - 你应该买入吗？